Free Trial
NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

Aprea Therapeutics logo
$1.50 +0.02 (+1.35%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$1.50 0.00 (-0.33%)
As of 10/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aprea Therapeutics Stock (NASDAQ:APRE)

Advanced

Key Stats

Today's Range
$1.48
$1.57
50-Day Range
$1.42
$1.88
52-Week Range
$1.37
$5.01
Volume
51,002 shs
Average Volume
41,339 shs
Market Capitalization
$8.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Hold

Company Overview

Aprea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

APRE MarketRank™: 

Aprea Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aprea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Aprea Therapeutics has a consensus price target of $15.50, representing about 933.3% upside from its current price of $1.50.

  • Amount of Analyst Coverage

    Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Aprea Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aprea Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aprea Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aprea Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aprea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.68% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently increased by 0.71%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Aprea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aprea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.68% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently increased by 0.71%, indicating that investor sentiment is decreasing.
  • Search Interest

    10 people have searched for APRE on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.63% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 34.19% of the stock of Aprea Therapeutics is held by institutions.

  • Read more about Aprea Therapeutics' insider trading history.
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

APRE Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Aprea Therapeutics Inc (APRE) - Investing.com
Aprea Therapeutics, Inc. (APRE) - Yahoo Finance
See More Headlines

APRE Stock Analysis - Frequently Asked Questions

Aprea Therapeutics' stock was trading at $3.29 at the start of the year. Since then, APRE shares have decreased by 54.4% and is now trading at $1.50.

Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its earnings results on Tuesday, August, 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.24. The firm had revenue of $0.12 million for the quarter. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative trailing twelve-month return on equity of 78.90%.

Aprea Therapeutics shares reverse split before market open on Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
8/12/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APRE
CIK
1781983
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$11.00
Potential Upside/Downside
+933.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.96 million
Net Margins
-1,645.01%
Pretax Margin
-1,645.01%
Return on Equity
-78.90%
Return on Assets
-62.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.34
Quick Ratio
5.34

Sales & Book Value

Annual Sales
$1.50 million
Price / Sales
5.83
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.55 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
5,830,000
Free Float
5,031,000
Market Cap
$8.75 million
Optionable
No Data
Beta
1.30
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:APRE) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners